Reliable supply of high-quality peptide drug intermediates and APIs is essential for pharmaceutical R&D. The global CDMO Service for Peptide APIs market was valued at US$ 3,986 million in 2025 and is anticipated to reach US$ 13,186 million by 2032 at a CAGR of 18.6%[reference:104], reflecting the growing demand for these critical materials.
Peptide drug intermediates include protected amino acids, resin-bound peptides, and partially assembled sequences. These materials are used in the synthesis of more complex peptides and are critical for efficient drug development. High-quality intermediates reduce the need for re-synthesis and improve overall process efficiency.
Peptide APIs (Active Pharmaceutical Ingredients) are the final drug substances used in pharmaceutical products. Our GMP facility produces peptide APIs under strict quality control, suitable for Phase I-III clinical trials and commercial products. We provide comprehensive documentation including batch records, validation reports, and stability data to support regulatory submissions.
Key considerations for peptide API supply include quality, scalability, and regulatory compliance. Quality must be maintained consistently across batches to ensure patient safety and product efficacy. Scalability ensures that supply can meet increasing demand as products progress through development. Regulatory compliance is essential for approval and market access.
At PeptideHub, we provide end-to-end support for peptide drug development, from intermediate supply through to commercial API manufacturing. Our experienced team works closely with customers to develop robust processes that meet regulatory requirements while optimizing cost and efficiency. We also provide regulatory support for IND and NDA filings, including comprehensive documentation of synthesis, characterization, and stability data.